Skip to content
drillr.ai
Sign up

CRBP

Corbus Pharmaceuticals Holdings, Inc.

NASDAQ · Healthcare · Biotechnology · US

$11.08
−3.32%
Ask drillr

  • Aug 6, 2026, 00:00 UTC

    Corbus Pharmaceuticals Holdings, Inc. reported a net loss of approximately $35.0 million for Q2 2026, with a net loss per share of $1.81.

  • Jul 28, 2026, 12:00 UTC

    The U.S. Food and Drug Administration cleared Corbus Pharmaceuticals to initiate its registrational study TEMPO-1 of CRB-701 in patients with second-line oropharyngeal squamous cell carcinoma.

    Source:

  • Jul 6, 2026, 00:00 UTC

    Corbus Pharmaceuticals Holdings, Inc. entered into a 2-year employment agreement with Leonardo Viana Nicacio to serve as Chief Medical Officer, effective August 3, 2026.